Lei Cao
Research Subjects
Lei Cao has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Bing Wu
Innovent Biologics (Suzhou) Co., Ltd., Suzhou, China
15 shared publications - Fufan He
Innovent Biologics (Suzhou) Co., Ltd., Suzhou, China
15 shared publications - Haiqing Ni
Innovent Biologics (Suzhou) Co., Ltd., Suzhou, China
15 shared publications - Huan Zhang
Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 shared publications - Li Li
Innovent Biologics (Suzhou) Co., Ltd., Suzhou, China
15 shared publications - Min Wu
Department of Pharmacology and Toxicology, Innovent Guoqing Academy, Suzhou, China
15 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S7: Epitope binning of indicated CD47 antibodies by biolayer interferometry.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S7: Epitope binning of indicated CD47 antibodies by biolayer interferometry.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S11: In vitro phagocytosis, in vivo anti-tumor efficacy, and body weight change data of TJH2201.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S11: In vitro phagocytosis, in vivo anti-tumor efficacy, and body weight change data of TJH2201.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S4: Hematological effects of biparatopic CD47 antibody, Hu5F9/B2B, in vitro and in vivo.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S4: Hematological effects of biparatopic CD47 antibody, Hu5F9/B2B, in vitro and in vivo.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Table S1: Sequence of TJH2201 (hz145A2/hz176G1)
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Table S1: Sequence of TJH2201 (hz145A2/hz176G1)
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
The CD47/SIRPα axis serves as a “do not eat me” signal, protecting normal cells from phagocytosis, but in the meantime, enabling immune evasion by tumor cells. Whereas substantial progress has been made in developing CD47 antagonists, achieving a balance between hematotoxicity and antitumor efficacy remains a critical challenge. In this study, we demonstrated that the bivalent anti-CD47 antibody, Hu5F9, caused severe anemia in both human CD47 knock-in mice lacking the CD47/SIRPα signal and human CD47/SIRPα double knock-in mice with complete signal, suggesting the CD47/SIRPα signal is not essential. Moreover, the single-arm CD47 antibody Hu5F9/gp120 exhibited only mild red blood cell (RBC) destruction in vitro and in vivo. These findings reveal that RBC toxicity induced by anti-CD47 antibodies is determined by the bivalency of the antibody rather than the CD47/SIRPα signal engagement. Based on this, we engineered TJH2201, a novel anti-CD47 antibody that avoids RBC agglutination while retaining high-affinity CD47 binding, robust signaling blockade, and enhanced pro-phagocytosis activity in vitro. In xenograft models with Raji and MV-4-11 cells, TJH2201 demonstrated potent antitumor activity without inducing body weight loss. These results suggest that TJH2201 is a promising CD47 antagonist that balances antitumor efficacy and hematologic safety, providing a new therapeutic approach for CD47-expressing malignancies.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
The CD47/SIRPα axis serves as a “do not eat me” signal, protecting normal cells from phagocytosis, but in the meantime, enabling immune evasion by tumor cells. Whereas substantial progress has been made in developing CD47 antagonists, achieving a balance between hematotoxicity and antitumor efficacy remains a critical challenge. In this study, we demonstrated that the bivalent anti-CD47 antibody, Hu5F9, caused severe anemia in both human CD47 knock-in mice lacking the CD47/SIRPα signal and human CD47/SIRPα double knock-in mice with complete signal, suggesting the CD47/SIRPα signal is not essential. Moreover, the single-arm CD47 antibody Hu5F9/gp120 exhibited only mild red blood cell (RBC) destruction in vitro and in vivo. These findings reveal that RBC toxicity induced by anti-CD47 antibodies is determined by the bivalency of the antibody rather than the CD47/SIRPα signal engagement. Based on this, we engineered TJH2201, a novel anti-CD47 antibody that avoids RBC agglutination while retaining high-affinity CD47 binding, robust signaling blockade, and enhanced pro-phagocytosis activity in vitro. In xenograft models with Raji and MV-4-11 cells, TJH2201 demonstrated potent antitumor activity without inducing body weight loss. These results suggest that TJH2201 is a promising CD47 antagonist that balances antitumor efficacy and hematologic safety, providing a new therapeutic approach for CD47-expressing malignancies.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S10: HE staining of spleens from hCD47/SIRPα KI mice 4 days after treatment.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S10: HE staining of spleens from hCD47/SIRPα KI mice 4 days after treatment.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S2: Binding ability and in vitro human RBC agglutination assay of Hu5F9/gp120.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S2: Binding ability and in vitro human RBC agglutination assay of Hu5F9/gp120.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S1: Hematological effects of Hu5F9 on hCD47 KI mice and hCD47/SIRPα DKI mice.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S1: Hematological effects of Hu5F9 on hCD47 KI mice and hCD47/SIRPα DKI mice.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S6: Microscopic images of in vitro RBC agglutination induced by Hu5F9/B2B at concentrations from 0.046 µg/ml to 100 µg/ml. Scale bar = 100 µm
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S6: Microscopic images of in vitro RBC agglutination induced by Hu5F9/B2B at concentrations from 0.046 µg/ml to 100 µg/ml. Scale bar = 100 µm
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S9: Microscopic images of in vitro RBC agglutination induced by TJH2201 at concentrations from 0.046 µg/ml to 100 µg/ml. Scale bar = 100 µm
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S9: Microscopic images of in vitro RBC agglutination induced by TJH2201 at concentrations from 0.046 µg/ml to 100 µg/ml. Scale bar = 100 µm